Background and Purpose-Outcome after mechanical thrombectomy for ischemic stroke may be influenced by blood pressure (BP). This study aims to assess the association of BP changes during general anesthesia versus conscious sedation with functional outcome after mechanical thrombectomy. Methods-SIESTA (Sedation vs Intubation for Endovascular Stroke Treatment) was a monocentric randomized trial of general anesthesia versus conscious sedation during mechanical thrombectomy involving BP target protocols. In this post hoc analysis, BP measurements were divided into 4 phases: preintervention, prerecanalization, postrecanalization, and postintervention. We examined the association between BP and functional outcomes (defined by improvement of 24-hour National Institutes of Health Stroke Scale [NIHSS] and 3-month modified Rankin Scale). Results-We found no association between the difference in systolic BP, diastolic BP, and mean arterial pressure from baseline to the different phases of intervention and NIHSS change after 24 hours. Only baseline diastolic BP was associated with a reduced improvement in NIHSS (β=0.17, P<0.01). There was no association of BP drops with a change in modified Rankin Scale at 3 months. About sedation, only baseline mean arterial pressure preintervention revealed significant associations (β=0.16, P<0.01) with less change in 24-hour NIHSS in conscious sedation group. Otherwise, there was no association for differences of any of the BP measurements with a change in 24-hour NIHSS and long-term functional outcome either in general anesthesia or the conscious sedation group when analyzed separately, consistent with our findings in the entire cohort. Doses of propofol (β=0.84, P=0.04) and norepinephrine (β=1.87, P=0.01) administered during intervention before recanalization were associated with reduced improvement of NIHSS at 24 hours. Conclusions-In a setting, where both sedation regimes general anesthesia and conscious sedation were performed according to strict protocols directed at avoiding BP extremes, our findings suggest that peri-interventional BP drops were not associated with either early neurological improvement or long-term functional outcome. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique identifier: NCT02126085. 
S everal randomized controlled trials [1] [2] [3] [4] [5] [6] and meta-analyses [7] [8] [9] have demonstrated that mechanical thrombectomy (MT) combined with standard treatment is superior to standard treatment alone including systemic thrombolytic therapy for patients with acute ischemic stroke because of large vessel occlusion. MT is, therefore, recommended in current international guidelines. 10, 11 However, >1/2 of patients still experience functional dependency (modified Rankin Scale [mRS] score of >2 after 3 months) despite this treatment. Not only the successful intervention itself but also periinterventional management may determine clinical outcome. This aspect has been insufficiently addressed in most MT randomized controlled trials published to date and represent a considerable challenge for treating physicians. Mode of sedation (eg, conscious sedation [CS] versus general anesthesia [GA] ) and aspects of airway management are the 2 most pressing issues in current literature. The effect of GA on functional outcome is particularly controversial. Several retrospective studies have strongly suggested that GA may be worse compared with non-GA in terms of functional outcome, mortality rates, and recanalization rates.
on peri-interventional management, SIESTA (Sedation vs Intubation for Endovascular Stroke Treatment), showed no statistically significant difference between patients treated with GA or CS with regard to the primary outcome of early neurological improvement. 13 These results were corroborated by 2 other recently published prospective trials.
14, 15 The results of these prospective trials contradict in part findings from previous retrospective studies. However, the validity and generalizability of these results are limited by the fact that these were single-center studies and not sufficiently powered to evaluate the long-term functional outcome. Among putatively decisive factors of peri-interventional management, blood pressure (BP) and BP variability around the period of vessel occlusion may be the most relevant. GA, in particular, is well-known to be associated with a substantial drop in BP during induction and maintenance of anesthesia.
This post hoc analysis from SIESTA aims to assess the association of BP changes during intervention with early neurological improvement and long-term functional outcome depending on the 2 sedation modes (CS and GA).
Methods

Design of the SIESTA Trial
Details on criteria for patient eligibility, methods, and the study protocol were published elsewhere. 16 Briefly, SIESTA was a single-center, prospective, randomized, parallel-group, and open-label treatment trial with blinded end point evaluation (PROBE [prospective randomized open blinded endpoint] design). Patients with a National Institutes of Health Stroke Scale (NIHSS) score of >10 and isolated or combined occlusion of the internal carotid artery or middle cerebral artery selected for MT were randomized 1:1 to either the nonintubated state in CS or to the intubated state in GA. Within the first 72 hours of treatment, oral and written informed consent was obtained from the patient or the patient's legal representative. The trial was approved by our institutional review board (Ethikkommission Medizinische Fakultät Heidelberg, ID S-650/2013).
Main Findings of the SIESTA Trial
The principal finding of SIESTA was that CS was not superior to GA with regard to the early functional outcome (defined as the change in NIHSS Score within 24 hours of patient admission). There were no differences in most secondary outcomes between both groups. 13 As expected, the substantial patient movement was less frequent in the GA group, but postinterventional complications (hypothermia, delayed extubation, and pneumonia) were more frequent. More patients were functionally independent in both groups (mRS score of 0-2 after 3 months). There were no differences in mortality at 3 months.
Secondary outcomes used for this preplanned post hoc analysis included hemodynamic monitoring parameters (baseline systolic BP 
Hemodynamic Data Assessment
Baseline characteristics (eg, NIHSS on admission, time from onset to groin puncture, and baseline Alberta Stroke Program Early CT Score) were extracted from the SIESTA database. Targets for SBP were set at 140 to 160 mm Hg in the SIESTA trial and were identical for both CS and GA. 16 For this post hoc analysis, BP measurements were divided into 4 different phases: (1) baseline BP at admission to the emergency room, (2) BP prerecanalization, (3) BP postrecanalization in the angio-suite, and (4) BP postintervention after admission to the N-ICU. Baseline BP was generally assessed as a single brachial measurement on admission to the neurological emergency room. Only in particular cases, 2 or more measurements were taken at baseline. BP measurements at baseline and during intervention were always peripheral brachial measurements. Further BP measurements were taken at regular 5-minute intervals during the intervention in both patient groups. Mean arterial pressure (MAP) was calculated based on SBP and DBP measurements using the formula for peripheral measurements of the MAP (MAP=(SBP+2×DBP)/3). Mean values of SBP, DBP, and MAP in the different time phases were subtracted from baseline levels to evaluate drop of BP between baseline and the different stages of the procedures. The prerecanalization phase included all measurements from groin puncture to final thrombectomy maneuver and postrecanalization phase included measurements from final recanalization to end of intervention. Data on BP postintervention measurements conducted in the N-ICU were extracted from the patient-management data documentation system. BP measurements were assessed as the first 2 documented brachial or invasive arterial measurements after admission to the N-ICU and were documented at regular 60-minute intervals during the stay of the N-ICU.
Additionally, extracted data included use and dosage of medications used to control BP (ie, catecholamines, analgesics, and sedatives). Induction of GA was standardized for all patients in SIESTA using etomidate, fentanyl, and rocuronium. For hemodynamic stabilization, all patients received crystalloid fluids during the intervention. Antihypertensive medications were not administered to patients with an SBP ≤185 mm Hg. Drugs used for peri-interventional management and to achieve target monitoring values were prespecified in our standard operating procedures for both GA and CS. 16 
Statistical Analysis
In a first step, we descriptively evaluated the BP measurements per phase by calculating mean values, SD, and the overall within-individual mean SD. The main aim of the analysis was to evaluate the predictive value of the change in BP from baseline to the subsequent phases on early neurological recovery (change in 24-hour NIHSS from admission) and long-term (3-month mRS) functional outcome. Therefore, we fitted linear and logistic regression models for NIHSS change and mRS (favorable [0-2] versus unfavorable [3] [4] [5] [6] ), respectively. The change in BP values was included as predictor where separate models were fitted for each subsequent phase.
We included either change in SBP and DBP or change in the MAP as predictors in our models and adjusted them for heart rate, baseline SBP and DBP or MAP, age, and baseline NIHSS (when analyzing mRS; see next paragraph). However, when we were analyzing mRS, this led to unstable models. Thus, we omitted the baseline measurements, age, and baseline NIHSS. Mean values per phase and person were calculated beforehand. We included all patients in the analysis no matter which sedation group they were randomized to within the SIESTA trial. We then repeated the above-described steps of the analysis separately for each group.
For each outcome (NIHSS change and mRS), 2 different modeling strategies were implemented. In the first, SBP change and DBP change were included as predictors. In the second, only MAP change was included. In both cases, models were adjusted for heart rate, baseline SBP and DBP or MAP, age, and baseline NIHSS (when analyzing mRS), as described above. In addition, we examined the predictive value of BP values per phase (instead of the change between phases) on the outcomes in separate models. Adjusted regression coefficients (β) or odds ratios, respectively, with 95% confidence intervals (CI) and P values (p) are presented for the change in BP resulting from the models. In an additional regression analysis, the predictive value of use and dosage of propofol, remifentanil, and norepinephrine on NIHSS change and mRS was evaluated (using the total data set). Mean values for each person and phase were calculated as it was done for BP values. Furthermore, the used models were adjusted for SBP, DBP, and heart rate.
A multiple imputation approach using chained equations 17 was used to deal with missing values where 50 data sets were generated. The results were obtained by applying Rubin rules. [17] [18] [19] A P value of <0.05 was considered as significant, although it was an exploratory analysis. No adjustment for multiple testing was applied because of the descriptive nature of the P values. The software R (version 3.3.1) with the packages xtable 19 (version 1.8-2) and mice (version 2.30) 17 was used for statistical analysis. We will present further sensitivity analyses (eg, models without imputation, regression models for each phase, separately, and others) in the online-only Data Supplement.
Results
Patient Characteristics
Data for all 150 patients enrolled in SIESTA were used in this post hoc analysis. Seventy-three (48.6%) and 77 (51.4%) of the recruited patients were allocated to GA and CS, respectively. In the study population, mean age was 71, baseline median NIHSS was 17, and 63% of the GA group and 65% of the CS group received intravenous thrombolysis with recombinant tissue-type plasminogen activator. Complete reperfusion (Thrombolysis in Cerebral Infarction [TICI] 2b or 3) was achieved in 89% versus 80.5%, improvement in 24-hour NIHSS was almost identical, and mRS 0 to 2 at 3 months was 37% versus 18.2% between GA and CS. Additional baseline, demographic, and clinical characteristics of the 2 treatment groups were published previously 13 ( Table I in the onlineonly Data Supplement) and for the entire cohort divided for decrease and increase of SBP are summarized in Table II in the online-only Data Supplement.
Thirty-nine patients in the CS and 73 in the GA group required norepinephrine to maintain SBP ≥140 mm Hg. The median number of BP measurements extracted from the angiographic protocol was 26 (interquartile range, 18.25-33) and the median procedure duration (groin puncture to end of procedure) was 105 minutes (interquartile range, 80-150). Additional descriptions concerning drugs and dosage are summarized in Table III through VI in the online-only Data Supplement.
Association Between Change in BP and Functional Outcome in the Entire Patient Population
The BP dynamics are summarized in the 
BP Associations According to Sedation Mode
For the GA group alone, the doses of propofol (β=0.84; [95% CI, 0.03-1.65]; P=0.04) and norepinephrine (β=1.87; [95% CI, 0.37-3.37]; P=0.01) administered during the intervention prerecanalization was associated with less improvement of NIHSS at 24 hours. There was no association of differences of any of the BP values with a change in 24-hour NIHSS in GA and CS group, consistent with the findings in the analysis of the entire population (Table VIII in the online-only Data Supplement). Analysis of CS group only revealed significant associations of baseline MAP preintervention (β=0.16, P<0.01) with less change in 24-hour NIHSS.
There was no association of the difference in any of the BP values with long-term functional outcome measured by mRS at 3 months in the GA and the CS group.
Results from further sensitivity analyses can be found in the online-only Data Supplement.
Discussion
This post hoc analysis of the SIESTA trial showed that drops in SBP and MAP from preintervention in all predefined phases of MT were not associated with reduced early neurological recovery in the analysis of the entire patient population. Only baseline DBP in the prerecanalization phase was significantly associated with reduced 24-hour NIHSS improvement. Our results did find an association between the use and dosage of drugs for BP adjustment (remifentanil, propofol, and norepinephrine) with a reduced improvement of 24-hour NIHSS. Most importantly, no association with longterm functional outcome was detected with drops in SBP, MAP, or DBP. A second analysis also found no association with a reduced improvement of early neurological recovery with BP drops when looking at both sedation groups (GA versus CS) separately except for a single association of baseline MAP preintervention in the CS group. In that analysis, use and cumulative dosage of propofol and norepinephrine were associated with reduced improvement of NIHSS as well. No association of BP changes with long-term functional outcome was found when analyzing separately for either GA or CS. Of note, these results were found when analyzing BP values from a trial under strict standards with BP safety margins for SBP between 120 and 180 mm Hg and target values between 140 and 160 mm Hg. It is very likely that BP dynamics play a decisive role in acute ischemic stroke, particularly when the acute ischemic stroke is caused by large vessel occlusion. Prerecanalization collateralization compensates during large vessel occlusion by supplying the ischemic penumbra with blood at least within a certain, very individual time frame, but it depends on a sufficient BP and hence cerebral perfusion pressure which is reflexively increased in the acute phase of stroke. Intubation for and maintenance of GA is often associated with a substantial drop in BP 20 and hypotension. Even fluctuations in BP have been shown to be disadvantageous in the acute phase of stroke. 21 Lowering of BP postrecanalization to avoid or reduce, for example, the risk of reperfusion edema is also controversial in clinical practice. Indeed, GA for thrombectomy was associated with hypotension and in previous studies [22] [23] [24] [25] and was linked with worse clinical outcomes. 24 To date, the impact of peri-interventional BP management on the functional outcome before, during, and after thrombectomy has not been sufficiently investigated, particularly not in prospective studies. Recent retrospective studies have suggested that functional outcome seems to be at least partly influenced by sedation mode used during thrombectomy. [22] [23] [24] 26 Few of these studies have addressed the question of peri-interventional BP management. Most have focused on the period before recanalization. These studies suggested that GA and a drop of an SBP <140 mm Hg 24 or MAP <70 mm Hg 27 were associated with a worse outcome. Another recently published study showed that lower intraprocedural BP is associated with a favorable outcome, 28 but these results were based on a single BP value. Whalin et al 27 demonstrated that BP drops >10% from baseline, in individual cases a MAP of <85 mm Hg, and every 10 mm Hg drop in MAP <100 mm Hg was associated with a worse functional outcome in a patient cohort treated solely with CS. The first study that focused on BP management in the postinterventional period showed different associations between BP dynamics during the first 24-hour postrecanalization and outcome in relation to recanalization state, indicating that a lower postprocedural BP may be favorable if recanalization was achieved. 29 However, as mentioned above all these studies were retrospective, and most were small.
The post hoc analysis of the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) showed a strong association between drops in BP during interventional treatment and long-term outcome defined as the mRS after 3 months in patients who were treated in GA. 30 We did not find this association in the GA group of SIESTA. It is important to note, however, that comparability may be limited by the fact that these studies had different sample sizes and primary end points, and that patients in the MR CLEAN trial as well as most other studies did not undergo randomization for sedation mode (CS versus GA) and did not include uniformly reported specification on physiology targets, choice of drugs used, or how anesthesia should be administered. It is, therefore, possible that more pronounced BP variations occurred in these studies and contributed to the clinical course and outcome, whereas BP extremes and variation may have been less severe in SIESTA. The predefined treatment target of SBP in SIESTA may explain why no associations of BP drops and clinical outcome were found in our post hoc analysis. Other studies on SBP have found that hypotension or a drop from baseline BP, mostly in connection with sedation modes such as GA, were associated with worse outcome. 15 all investigating the optimal peri-interventional management and monitoring, including strict protocols on BP management, have reported a negative impact of GA on functional outcome after thrombectomy.
In contrast to earlier studies, we did not find a significant association of BP changes with short-term improvement or long-term functional outcome after MT. Either such influence does not exist, or-more likely-SIESTAs protocols with strict target values may have prevented a greater and longterm impact. Potential advantages of GA, when compared with CS (eg, improved interventional workflow, less agitation, standardized relative hypoventilation, and improved collateralization), may have counterbalanced BP drops. Importantly, SIESTA was powered to investigate the effect of peri-interventional management on clinical outcome in the short-term and our sample size of only 150 patients limited our ability to detect effects on long-term functional outcome.
Our study has several limitations. First, SIESTA was a single-center study and generalization of its findings is therefore difficult; this is particularly true for a post hoc analysis. Second, the relatively small sample size limits the insights from this explorative study. Third, the baseline BP variable is based on a single measurement and is, therefore, more prone to measurement errors. Fourth, all BP measurements were noninvasive and brachial measurements could underestimate hypertensive BP levels and produce higher values at the lower end of the spectrum. Fifth, the choice of phases in which BP measurements were analyzed were arbitrary and of different lengths in individual patients. This may have confounded the findings and limits comparability to other studies. Furthermore, we did not analyze the impact of the variability (or SD) within the phases on the outcomes which may be of interest in future investigations.
Conclusions
Our results suggest that drops in BP from baseline were neither associated with reduced early neurological improvement after 24 hours nor with long-term functional outcome, irrespective of the choice of either GA or CS. This may be explained by the fact that GA and CA were performed according to protocols, which included strict physiological target parameters and were aimed at avoiding extremes. Hence, we assume that a target SBP range from 140 to 160 mm Hg during the intervention may reasonable and safe. It is still possible that sedation management without strict BP target ranges may result in less favorable long-term functional outcomes particularly if collateralization is otherwise compromised. Hence, BP drops during MT should still be avoided.
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